Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results. (3rd July 2018)

• Record Type: Journal Article
• Authors: Schwarz, Christoph; Mahr, Benedikt; Muckenhuber, Moritz; Wekerle, Thomas
• Is Part Of: Expert review of clinical immunology. Volume 14:Number 7(2018)
• Page Start: 583
• Page End: 592
• Publication Date: 2018-07-03
• Subjects: Costimulation blockade -- CTLA4Ig -- transplantation; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2018.1485489
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : The B7/CD28/CTLA4 signaling cascade is the most thoroughly studied costimulatory pathway and blockade with CTLA4Ig (abatacept) or its derivative belatacept has emerged as a valuable option for pharmacologic immune modulation. Several clinical studies have ultimately led to the approval of belatacept for immunosuppression in kidney transplant recipients. Areas covered : This review will discuss the immunological background of costimulation blockade and recent preclinical data and clinical results of CTLA4Ig/belatacept. Expert commentary : The development of belatacept is a major advance in clinical transplantation. However, in spite of promising results in preclinical and clinical trials, clinical use remains limited at present, in part due to increased rates of acute rejection. Recent efforts showing encouraging progress in refining such protocols might be a step toward harnessing the full potential of costimulation blockade-based immunosuppression.